Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Transplantation. 2018 Jan;102(1):e30-e38. doi: 10.1097/TP.0000000000001958.
Limited data are available regarding the long-term effects of pancreas transplantation on the progression of diabetic retinopathy (DR) and the incidence and associated risk factors for early worsening of DR.
Patients who underwent successful pancreas transplantation between January 2007 and October 2015 and were followed for 1 year or longer were consecutively enrolled. Variables regarding demographic, systemic, metabolic, and surgical factors were reviewed for each patient. DR progression was defined as (i) development or aggravation of macular edema requiring intravitreal anti-VEGF injections and/or (ii) progression of DR severity requiring panretinal photocoagulation (PRP) and/or pars planar vitrectomy (PPV). Early worsening was defined as progression within 1 year of posttransplant.
Three hundred three eyes of 153 patients were included in the analysis. At the pretransplant ocular evaluation, 221 eyes (72.9%) showed advanced DR with history of PRP and/or PPV. During a mean follow-up period of 4.2 years, 62 eyes (20.5%) experienced DR progression, and early worsening was noted in 57 eyes (18.8%). DR with recent PRP within pretransplant 1 year and pancreas transplant alone were significant risk factors for early worsening.
In 4 of 5 patients who received pancreas transplant, the degree of DR remained stable over time after transplantation. Meanwhile, early worsening of DR could occur in patients at risk, particularly within the first posttransplant year. We suggest that physicians should have a high index of suspicion and carefully monitor for early worsening of DR and timely manage possible ocular deterioration.
关于胰腺移植对糖尿病视网膜病变(DR)进展的长期影响,以及 DR 早期恶化的发生率及其相关危险因素,目前仅有有限的数据。
连续纳入 2007 年 1 月至 2015 年 10 月期间成功接受胰腺移植且随访 1 年以上的患者。回顾每位患者的人口统计学、系统性、代谢和手术因素等变量。DR 进展定义为:(i)需要玻璃体内抗 VEGF 注射治疗的黄斑水肿的发展或加重,和/或(ii)需要全视网膜光凝(PRP)和/或经平坦部玻璃体切除术(PPV)治疗的 DR 严重程度恶化。早期恶化定义为移植后 1 年内进展。
共纳入 153 例患者的 303 只眼。在移植前眼部评估时,221 只眼(72.9%)有 PRP 和/或 PPV 治疗史,处于晚期 DR。在平均 4.2 年的随访期间,62 只眼(20.5%)发生 DR 进展,57 只眼(18.8%)出现早期恶化。移植前 1 年内最近有 PRP 和单纯胰腺移植是早期恶化的显著危险因素。
在接受胰腺移植的 5 例患者中,4 例患者的 DR 程度在移植后随时间推移保持稳定。同时,高危患者可能会出现 DR 的早期恶化,特别是在移植后的第 1 年内。我们建议医生应保持高度警惕,密切监测 DR 的早期恶化,并及时处理可能出现的眼部恶化。